Immunogenicity, Safety and Reactogenicity of GSK Biologicals' Tritanrix-HepB Low Thio/Hib2.5 Godollo Compared to GSK Biologicals' Tritanrix-HepB/Hiberix Godollo When Administered as a 3-dose Primary Vaccination Course to Healthy Infants

Trial Profile

Immunogenicity, Safety and Reactogenicity of GSK Biologicals' Tritanrix-HepB Low Thio/Hib2.5 Godollo Compared to GSK Biologicals' Tritanrix-HepB/Hiberix Godollo When Administered as a 3-dose Primary Vaccination Course to Healthy Infants

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Feb 2011

At a glance

  • Drugs DTP-hepatitis B vaccine; Hib vaccine; Hib-DTP hepatitis B vaccine (Tritanrix-HepB/Hiberix)
  • Indications Diphtheria; Haemophilus infections; Hepatitis B; Pertussis; Tetanus
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 13 Feb 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top